Most articles about testosterone therapy spend their time telling you why you might want it. This one does the opposite, and on purpose. Before any responsible clinician writes a prescription, they spend a quiet few minutes asking a different question: is there any reason this man should not start? That step is not about being afraid of testosterone. It is the part of the job that keeps treatment safe.
Think of it the way a pilot thinks about a pre-flight checklist. The checklist is not a sign that flying is dangerous. It is the reason flying is safe. Screening for the reasons not to start TRT works the same way. For most men with a genuine diagnosis, these checks come back clear and treatment goes ahead. For a smaller group, the checks catch something that needs to be sorted out first, or that makes testosterone the wrong tool entirely.
So this is the safety side of the conversation. Below are the situations where a careful doctor pumps the brakes, what counts as an absolute “not now” versus a “let’s deal with this first,” and why each one is on the list. The goal is not to talk you out of TRT. It is to help you walk into that appointment understanding exactly what your clinician is checking, and why.
What Is the Difference Between an Absolute and a Relative Contraindication?
It helps to know the two categories your doctor is sorting into. An absolute contraindication means testosterone should not be started, full stop, because the risk is real and not something you can simply monitor around. A relative contraindication (sometimes called a precaution) means there is a problem that has to be evaluated, controlled, or treated first, after which TRT may become reasonable again.
The major medical guideline here, from the Endocrine Society, lays out a clear list of conditions where it recommends against starting testosterone, either outright or until the issue is addressed (Bhasin et al., 2018, PMID 29562364, DOI 10.1210/jc.2018-00229). According to PubMed, that guideline is the backbone of how most clinicians approach this screening. Almost everything that follows traces back to it.
The practical takeaway is that very few of these are permanent doors slammed shut. Most are “fix this first” gates. Knowing which is which is half the conversation.
Could TRT Make a Hidden Prostate or Breast Cancer Worse?
This is the one that sits at the top of every clinician’s list. Testosterone can act as fuel for certain hormone-sensitive cancers, so an active, untreated prostate cancer or a male breast cancer is an absolute reason not to start (Bhasin et al., 2018, PMID 29562364, DOI 10.1210/jc.2018-00229). Male breast cancer is rare, but it is on the list precisely because the stakes are high.
The harder, more common scenario is the man who has not been diagnosed with anything, but whose screening throws up a flag. That is why the workup before TRT includes a prostate check and a PSA (prostate-specific antigen, a blood marker that can rise with prostate problems). The guideline advises holding off and getting a urology evaluation first if there is a palpable prostate nodule or hardening, a PSA above 4 ng/mL, or a PSA above 3 ng/mL in men at higher risk, such as those with a family history (Bhasin et al., 2018, PMID 29562364, DOI 10.1210/jc.2018-00229).
Notice the logic. An unevaluated nodule or a high PSA is not proof of cancer. It is an unanswered question, and you do not start testosterone with an unanswered prostate question on the table. You answer it first. This is also why the large TRAVERSE safety trial deliberately screened out men with a PSA above 3 ng/mL before enrolling anyone, so its reassuring overall findings apply to men already checked and cleared, not to men with an open prostate concern (Lincoff et al., 2023, PMID 37326322, DOI 10.1056/NEJMoa2215025).
What If My Blood Is Already Too Thick?
Testosterone tells your bone marrow to make more red blood cells. For most men that is harmless, but in some it pushes the hematocrit (the percentage of your blood made up of red cells) too high, a state called polycythemia or erythrocytosis. Thicker blood flows less easily and can raise the risk of clots.
This is why a baseline blood count matters before you start. If your hematocrit is already elevated, that is a reason to hold off until it is investigated and controlled, rather than pouring testosterone on top of it (Bhasin et al., 2018, PMID 29562364, DOI 10.1210/jc.2018-00229). The concern is not theoretical. According to PubMed, one large study of men on testosterone found that those who developed polycythemia, defined as a hematocrit at or above 52%, had a higher risk of major cardiovascular events and venous clots in the first year compared with men whose hematocrit stayed normal (odds ratio 1.35) (Ory et al., 2022, PMID 35050717, DOI 10.1097/JU.0000000000002437).
The reassuring half of that same study is just as important: men on testosterone who did not develop polycythemia showed no such excess risk. That is the whole argument for screening and monitoring. The hematocrit is a number you can watch, and acting on it early is what keeps this risk small.
Should I Wait If I Have Untreated Sleep Apnea?
Severe, untreated obstructive sleep apnea (where the airway repeatedly collapses during sleep, dropping your oxygen) is on the caution list for two reasons. Testosterone may worsen the apnea itself in some men, and untreated apnea independently drives up the hematocrit and cardiovascular strain, stacking risk on top of the blood-thickening concern above (Bhasin et al., 2018, PMID 29562364, DOI 10.1210/jc.2018-00229).
The key word, again, is untreated. This is a fix-first gate, not a permanent no. If you snore heavily, wake unrefreshed, or your partner has noticed you stop breathing at night, that deserves a proper sleep evaluation before TRT, not after. Treated, well-controlled apnea is a very different situation. There is also a meaningful overlap to know about: poor sleep, low testosterone, and erectile difficulty often travel together, which is worth untangling with your clinician rather than assuming testosterone alone is the answer (Barone et al., 2022, PMID 35408895, DOI 10.3390/ijms23073535).
What If My Heart Is Not Stable?
Uncontrolled, severe heart failure is a reason to wait. Testosterone can cause fluid retention, which is exactly what a struggling heart does not need, and a recent heart attack or stroke (within the last six months) is also on the hold list (Bhasin et al., 2018, PMID 29562364, DOI 10.1210/jc.2018-00229). The thread running through these is timing and control, not a blanket ban on testosterone for anyone with heart history.
Here is where the recent evidence is genuinely reassuring, and worth keeping in proportion. The TRAVERSE trial enrolled more than 5,000 men who had heart disease or were at high risk for it, and found that testosterone was not inferior to placebo for major cardiac events such as heart attack, stroke, and cardiovascular death (Lincoff et al., 2023, PMID 37326322, DOI 10.1056/NEJMoa2215025). That is the strongest cardiovascular safety data we have, and in early 2025 the FDA removed the old cardiovascular boxed warning from testosterone labels on the strength of it.
But the same trial, and the same regulatory review, kept the picture honest. TRAVERSE saw higher rates of atrial fibrillation (an irregular heartbeat) and pulmonary embolism (a clot in the lung) in the testosterone group (Lincoff et al., 2023, PMID 37326322, DOI 10.1056/NEJMoa2215025). And in February 2025, alongside removing the heart-attack warning, the FDA added a new warning that testosterone can raise blood pressure, after post-marketing studies showed exactly that across the whole drug class (FDA, 2025). So if your blood pressure already runs high, or you have a history of an irregular heartbeat or clots, those belong in the conversation before you start, not as reasons for blanket fear, but as things a careful clinician factors in.
I Want Children Soon. Is TRT a Problem?
Yes, and this is the contraindication men are most surprised by, so it is worth being direct. Testosterone you take from outside the body switches off the brain’s signal to the testicles, and that signal is what drives sperm production. The result is that exogenous testosterone suppresses spermatogenesis, often dramatically, and can drop sperm counts toward zero (Fusco et al., 2021, PMID 33292112, DOI 10.2174/1381612826666201207104340).
The guideline is explicit that men planning fertility in the near term should not start standard testosterone therapy (Bhasin et al., 2018, PMID 29562364, DOI 10.1210/jc.2018-00229). According to PubMed, while many men do see sperm counts recover after stopping, the evidence on how long that takes is mixed, and recovery is not guaranteed to be fast or complete (Fusco et al., 2021, PMID 33292112, DOI 10.2174/1381612826666201207104340).
The good news is that this is a “wrong tool” problem, not a dead end. If you have low testosterone and you want to preserve fertility, there are alternative approaches that raise your own testosterone without shutting the testicles down, and a clinician who treats male fertility can walk you through them. The mistake is starting standard TRT first and discovering the fertility cost later.
Are There Other Situations Where I Should Wait?
A few more deserve a mention, because they round out the checklist. Severe, uncontrolled lower urinary tract symptoms (the bothersome urinary problems often linked to an enlarged prostate) are a reason to hold off until they are better managed (Bhasin et al., 2018, PMID 29562364, DOI 10.1210/jc.2018-00229). And a known thrombophilia (an inherited or acquired tendency to form clots) or a recent venous clot calls for real caution, given testosterone’s effect on the blood and the clot signals seen in TRAVERSE (Bhasin et al., 2018, PMID 29562364, DOI 10.1210/jc.2018-00229; Lincoff et al., 2023, PMID 37326322, DOI 10.1056/NEJMoa2215025).
None of these is meant to scare you off. Each one is simply a reason your clinician would rather pause, sort the issue out, and reassess, than press ahead and hope.
What Should You Ask Your Clinician Before Starting TRT?
Walking in with the right questions turns this from something done to you into a decision you share. A few worth raising:
- Have we confirmed my low testosterone properly, on more than one morning blood test, before talking about treatment?
- What did my prostate exam and PSA show, and is anything there worth checking before I start?
- What is my baseline hematocrit, and what number would make you pause or stop therapy?
- Do I have any sleep apnea, heart, blood pressure, or clotting history we should deal with first?
- Do I want to father children in the foreseeable future, and if so, what does that change?
- How will you monitor me once I start, and how often?
If your clinician welcomes these questions, you are in good hands. Good TRT care is defined as much by what gets checked before the first dose as by the prescription itself.
Conclusion
The honest summary is this: testosterone therapy is right for many men and wrong for others, and the difference is usually visible before treatment ever begins. Most reasons not to start are not permanent bans. They are gates, an unanswered prostate question, a blood count that is already high, untreated sleep apnea, an unstable heart, a near-term wish for children. Deal with what can be dealt with, and for many men the path to treatment reopens. Walk through the gate without checking, and you trade a fixable problem now for a harder one later. A clinician screening for the reasons not to treat is not afraid of testosterone. They are doing the part of the job that makes saying yes safe.
Related reading
- how hematocrit is tracked on testosterone therapy
- what the TRAVERSE trial actually found
- the link between sleep apnea and erectile dysfunction
References
- Bhasin et al., Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab 2018. DOI: 10.1210/jc.2018-00229
- Ory et al., J Urol 2022. DOI: 10.1097/JU.0000000000002437
- Lincoff et al., N Engl J Med 2023 (TRAVERSE). DOI: 10.1056/NEJMoa2215025
- Fusco et al., Curr Pharm Des 2021. DOI: 10.2174/1381612826666201207104340
- Barone et al., Int J Mol Sci 2022. DOI: 10.3390/ijms23073535
- FDA Drug Safety Communication (regulatory primary source). link
